Navigation Links
Nephros Has Commenced Rights Offering
Date:2/11/2011

shares of common stock and a warrant to purchase 386 shares of common stock (418 units × 0.924532845 = 386.4547292, rounded down to 386, the nearest whole number) at an exercise price of $0.02 per share for a period of five years following the issue date of the warrant.

Holders that exercise their rights, if accepted, will receive the components of the units (one share of common stock and one warrant to purchase 0.924532845 shares of common stock per unit) after the close of the rights offering.  Nephros will not issue and holders will not receive units in the rights offering.

Nephros stockholders who exercise their basic subscription privilege in full may also exercise an over-subscription privilege to subscribe for additional units not subscribed for by other stockholders at the same subscription price of $0.02 per unit. If there is an insufficient number of units available to fully satisfy all over-subscription privilege requests, the available units will be allocated proportionately among stockholders who exercise their over-subscription privileges based on the number of units each such stockholder subscribed for under the basic subscription privilege.

The subscription rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on February 28, 2011, unless Nephros extends the subscription period in its sole discretion, but in no event by more than 60 days from the date of the prospectus contained in the registration statement.

The prospectus contains a description of the rights offering and other information.  Stockholders are urged to read the prospectus carefully.  Morrow & Co., LLC is the information agent for the rights offering. Stockholders may direct questions regarding the rights offering or requests for additional copies of the prospectus or other offering materials to Morrow & Co., LLC at (800) 414-4313, 407 West Avenue, Stamford, Connecticut 06902.  The rights
'/>"/>

SOURCE Nephros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nephros Rights Offering Registration Statement Declared Effective
2. Nephros Reports 2010 Third Quarter Financial Results
3. Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
4. Nephros Reports 2010 Second Quarter Financial Results
5. Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System
6. Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
7. Nephros Reports 2010 First Quarter Financial Results
8. Nephros Signs Development Agreement with STERIS
9. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
10. Nephros Reports 2009 Third Quarter Financial Results
11. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... September 22, 2014 Final ... 25   The second edition of the ... excited to announce the final nominations for the 2014 ... on the evening of September 25 at The Taj Mahal Palace, ... applicants based on a variety of qualitative and quantitative ...
(Date:9/22/2014)... Sept. 22, 2014  Elusys Therapeutics, Inc. (Elusys), ... infectious disease, today announced it has completed three ... obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in development ... from these studies support the safety and tolerability ... the intended therapeutic dose. The conclusion of these ...
(Date:9/22/2014)... , Sept. 22, 2014  Aethlon Medical, ... therapeutic devices to address infectious disease, cancer and ... Advanced Research Projects Agency (DARPA) has informed the ... to proceed with year four of a five-year ... on September 30, 2011 under DARPA,s Dialysis-Like Therapeutics ...
Breaking Medicine Technology:Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4
(Date:9/22/2014)... Hamilton, ON (September 22, 2014) South Asians living ... and double the rate of diabetes compared with while ... was published today in the Canadian Medical Association ... http://www.cmajopen.ca/content/2/3/E183.full , One of the fastest-growing ethnic ... million South Asian people living in Canada, comprising about ...
(Date:9/22/2014)... NJ. September 22, 2014. Kessler researchers have published ... 10-week psychoeducational wellness program in people with multiple ... overall mental health, perceived stress, and pain. ... for individuals living with MS: Description and outcomes" ... in the International Journal of MS Care ...
(Date:9/22/2014)... News) -- Two new prescription devices approved by the ... relief for people with migraine headaches who don,t tolerate ... One device -- the Cefaly -- is designed to ... -- is meant to be used when migraines first ... have been looking for alternative migraine treatments. Because these ...
(Date:9/22/2014)... Severe weather can occur with little warning, so ... part of National Preparedness Month, Amica Insurance is offering ... the unexpected:, , Build an emergency supply kit. ... one gallon of water per person per day for at least ... that includes pets so your family knows what to do and ...
(Date:9/22/2014)... New York / Westchester County, NY (PRWEB) September 22, ... Plastic Surgery (NYGPS) has joined the Department of Surgery ... The newly named Mount Sinai Doctors New York Group ... and the lower Hudson Valley access to a team ... plastic surgery techniques. Additionally, C. Andrew Salzberg, MD, ...
Breaking Medicine News(10 mins):Health News:Higher risk of heart disease for South Asians in Canada 2Health News:Noninvasive Devices May Help Migraines, FDA Says 2Health News:Amica Shares Tips for National Preparedness Month 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3
... RIVERWOODS, Ill., June 10 As more and more employees ... a smaller and smaller percentage of them are actually signing ... the findings of the Spencer,s Benefits Reports 2009 ... COBRA in the 2008 plan year at companies covered by ...
... ARLINGTON, Va., June 10 The Generic Pharmaceutical Association ... and CEO Kathleen Jaeger regarding publication of the Federal ... , , "Today,s report from the FTC ... forward on passage of legislation that brings affordable biogenerics ...
... RIVERSIDE, California and NUREMBERG, Germany, June 10 ,Ziehm Imaging ... and Drug,Administration (FDA) has given 510k clearance for the ... RFD, for marketing and,sales within the United States. Designed ... the Ziehm Vision RFD,mobile C-arm combines the latest flat-panel ...
... Corporation (Nasdaq: KNSY ) is scheduled to present ... 18, 2009. , , Joseph W. Kaufmann, Kensey ... at approximately 9:00 a.m. (ET). To hear the live ... . The presentation materials will also be available on ...
... bacteria,s structure, , WEDNESDAY, June 10 (HealthDay News) -- ... a vacation. , Now, researchers have figured out how ... coli, or ETEC -- are able to make ... or "fimbriae" to attach, or bind, to the intestinal ...
... 2009, the Institute for Quality and Efficiency in Health ... assessment of certain newer antidepressants. The project commissioned by ... the benefit of three agents, reboxetine, mirtazapine and bupropion ... German drug approval status. Interested parties and institutions may ...
Cached Medicine News:Health News:Spencer's Benefits Reports COBRA Survey Finds Recession Takes Hold: More Were Eligible, Fewer Signed Up, Costs Stay High 2Health News:Spencer's Benefits Reports COBRA Survey Finds Recession Takes Hold: More Were Eligible, Fewer Signed Up, Costs Stay High 3Health News:Spencer's Benefits Reports COBRA Survey Finds Recession Takes Hold: More Were Eligible, Fewer Signed Up, Costs Stay High 4Health News:GPhA Statement on FTC Report on 'Follow-on Biologic Drug Competition' 2Health News:GPhA Statement on FTC Report on 'Follow-on Biologic Drug Competition' 3Health News:SVS 2009: Ziehm Imaging Sets a New Standard in Mobile Imaging With the Ziehm Vision RFD 2Health News:SVS 2009: Ziehm Imaging Sets a New Standard in Mobile Imaging With the Ziehm Vision RFD 3Health News:Finding May Lead to Vaccine for Traveler's Diarrhea 2Health News:Preliminary report on antidepressants published 2
... ANA and ENA assays can be ... for antinuclear antibodies, which are associated ... as Systemic lupus erythematosus (Lupus), Sjgren's ... systemic sclerosis, scleroderma, polymyositis, dermatomyositis, and ...
... assays can be used to screen ... which are associated with various systemic ... erythematosus (Lupus), Sjgren's syndrome, mixed connective ... polymyositis, dermatomyositis, and Raynaud's phenomenon. They ...
... Fluorescence Assay (IFA) for IgG Antinuclear ... the qualitative and semi-quantitative detection of ... human serum. Detection of ANA in ... aid in the diagnosis of autoimmune ...
Anti-Tg and Anti-TPO are two major autoantibodies implicated in autoimmune related thyroiditis and aid in the differential diagnosis of Hashimoto's thyroiditis and Graves' disease....
Medicine Products: